CA-GLOBALITY
29.7.2021 14:02:13 CEST | Business Wire | Press release
Globality , the leading AI-powered digital solution for sourcing services, and Allegis Global Solutions (AGS), the leading provider of global workforce solutions, today announced a partnership that transforms services procurement management so organizations can realize the maximum value from their services spend.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729005144/en/
By closing the loop between sourcing and spend management, the partnership will deliver increased value through the end-to-end procurement process, incorporating AI-powered insights every step of the way. As a result, AGS customers will benefit from real-time data and intelligence on supplier performance in Globality’s self-serve Platform, leading to better buying decisions.
“Today’s workforce is dramatically different than it was a year ago, with global enterprises more dependent than ever on external suppliers for their consulting, marketing, IT, HR, legal and other service needs for agility and adaptability,” said Globality Chief Revenue Officer Keith Hausmann. “Without the right technology, processes and information in place, businesses historically will spend 10% to 30% more on outside services. Completing the source-to-pay process with this new integration ensures AGS customers have greater insights for all their high-value services, resulting in more efficient procurement decisions, faster speed to market and better supplier quality.”
Delivering a path to improved management of services spend, the partnership provides multiple advantages:
- Faster engagement: Increasing efficiencies and accelerating speed to market by automating procurement processes with AI-powered, self-serve sourcing
- Better supplier quality: Revealing the best-performing suppliers using data-enabled intelligence to facilitate continuous machine learning
- Increased user satisfaction: Boosting adoption of the overall procurement strategy and enhancing compliance through a consumer-like, intuitive sourcing experience
- Strategic transformation: Enabling better buying decisions with more compliant supplier engagement, competitively sourced spend and greater insights into what is delivered after the contract is signed
- End-to-end value realization: Identifying optimal solutions at the best available cost and incorporating feedback that makes future sourcing activity on the Platform even more robust and intelligent
With strategic sourcing increasingly viewed as a critical source of transformational innovation for global enterprises, companies are actively seeking ways to improve their bottom line and increase efficiency gains. Globality’s Platform transforms the sourcing of high-value services by automating the demand creation, supplier identification, proposal evaluation and statement of work (SOW) creation process with an intuitive self-serve experience. Companies can dynamically source the best-fit supplier for every complex service, while AGS manages delivery, generating actionable, real-time insights and identifying opportunities for additional savings.
“From opportunity to RFP, selection, management and performance tracking, an AGS and Globality solution closes the loop on strategy and execution to deliver a continuous cycle of performance improvement and an improved end-user experience,” said AGS Head of Procurement Solutions Strategy Jon Kesman. “This end-to-end solution ensures companies only contract for what they need and no longer leave significant dollars on the table with services being poorly sourced or left unmanaged after the contract is signed.”
“The AGS and Globality solution gives users faster engagement by modernizing and simplifying what can be a cumbersome RFP process when it comes to services and ensuring better supplier quality through continuous AI-driven learning, which increases end-user satisfaction and enhances compliance in the procurement process with its easy-to-use interface,” Kesman added.
To learn more about the partnership or schedule a demo, visit https://learn.allegisglobalsolutions.com/en-us/globality .
About Globality
Globality is a Silicon Valley-headquartered technology company co-founded by Joel Hyatt and Lior Delgo to revolutionize how companies buy and sell services. Through its AI-powered Platform and marketplace, Globality is bringing digital transformation to the sourcing industry. Globality’s AI digital solution replaces the archaic analog Request for Proposal, efficiently and effectively scoping needs, managing demand, matching companies with outstanding suppliers that meet their specific service needs and cutting the sourcing process from months to hours while delivering savings of 20% or more. In January 2021, Globality raised $138 million from Sienna Capital and the SoftBank Vision Fund, bringing the total investment it has raised since its founding five years ago to $310 million. For more information, visit Globality’s website at www.globality.com .
About Allegis Global Solutions
Allegis Global Solutions (AGS) is the leading provider of workforce solutions. AGS transforms the way the world acquires talent in order to deliver immediate and lasting impact. Through decades of industry experience, and with services across 60+ countries, AGS knows what it takes to innovate, consult, design and implement successful, creative and data-driven talent solutions across all workforce categories. Learn more at www.allegisglobalsolutions.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210729005144/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom